Charles Schoch

CIK: 0002007349

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (42.9%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (57.1%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CADL

Candel Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

CADL
Candel Therapeutics, Inc.
Jan 26, 2026
Award(A)
Stock Option (Right to Buy)
Direct
232K shares-
CADL
Candel Therapeutics, Inc.
Jun 25, 2025
Award(A)
Direct
5.4K shares at avg. $4.67$25K
CADL
Candel Therapeutics, Inc.
Jun 20, 2025
Award(A)
Stock Option (Right to Buy)
Direct
50K shares-
CADL
Candel Therapeutics, Inc.
Mar 17, 2025
Sale(S)
Direct
5K shares at avg. $8.83$44K
CADL
Candel Therapeutics, Inc.
Feb 12, 2025
Award(A)
Stock Option (Right to Buy)
Direct
83K shares-
CADL
Candel Therapeutics, Inc.
Jan 15, 2025
Sale(S)
Direct
9.5K shares at avg. $7.22$69K
CADL
Candel Therapeutics, Inc.
Jan 8, 2025
Sale(S)
Direct
10K shares at avg. $8.22$82K

		Type	Shares	Price		Ownership
Jan 26, 2026	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	232,000	-	-	Direct
Jun 25, 2025	CADL Candel Therapeutics, Inc.	Award(A)	5,353	$4.67	$24,999	Direct
Jun 20, 2025	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	50,000	-	-	Direct
Mar 17, 2025	CADL Candel Therapeutics, Inc.	Sale(S)	5,000	$8.83	$44,169	Direct
Feb 12, 2025	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	83,000	-	-	Direct
Jan 15, 2025	CADL Candel Therapeutics, Inc.	Sale(S)	9,511	$7.22	$68,717	Direct
Jan 8, 2025	CADL Candel Therapeutics, Inc.	Sale(S)	9,971	$8.22	$81,944	Direct

1-7 of 7 transactions

About Schoch Charles

Schoch Charles (SEC CIK 0002007349) files insider reports with the SEC as Chief Financial Officer of Candel Therapeutics, Inc. (CADL).

Signal8 holds 7 ownership filings by Schoch Charles, all Form 4s, filed between Jan 10, 2025 and Jan 28, 2026. Those filings report 7 transactions, from Jan 8, 2025 to Jan 26, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Schoch Charles's filings is in NEEDHAM, MA.

Recent filings by Schoch Charles

Jan 26, 2026: Grant or award of CADL derivative securities (Form 4, code A).
Jun 25, 2025: Grant or award of CADL shares (Form 4, code A).
Jun 20, 2025: Grant or award of CADL derivative securities (Form 4, code A).
Mar 17, 2025: Open-market sale of CADL shares (Form 4, code S).
Feb 12, 2025: Grant or award of CADL derivative securities (Form 4, code A).

Other insiders filing for Candel Therapeutics, Inc. (CADL)

Loggia Nicoletta, Director
PAPA JOSEPH C, Director
Manning Paul B, Director
Tak Paul Peter, Chief Executive Officer
Zimmermann Martine, Director
Tyagarajan Seshu, Chief Technology Officer

How to read Form 4 transaction codes